Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 11 04:00PM ET
4.14
Dollar change
+0.40
Percentage change
10.70
%
IndexRUT P/E- EPS (ttm)-2.19 Insider Own7.51% Shs Outstand62.07M Perf Week15.32%
Market Cap259.66M Forward P/E- EPS next Y-2.06 Insider Trans0.00% Shs Float58.01M Perf Month14.68%
Income-136.37M PEG- EPS next Q0.21 Inst Own92.44% Short Float9.53% Perf Quarter-14.29%
Sales41.02M P/S6.33 EPS this Y-1235.52% Inst Trans-7.33% Short Ratio6.69 Perf Half Y-76.40%
Book/sh0.92 P/B4.49 EPS next Y-2.97% ROA-53.82% Short Interest5.53M Perf Year-18.50%
Cash/sh2.24 P/C1.85 EPS next 5Y- ROE-118.91% 52W Range2.95 - 21.88 Perf YTD-56.96%
Dividend Est.- P/FCF- EPS past 5Y48.88% ROI-155.91% 52W High-81.08% Beta2.09
Dividend TTM- Quick Ratio2.69 Sales past 5Y15.77% Gross Margin61.08% 52W Low40.29% ATR (14)0.21
Dividend Ex-Date- Current Ratio2.71 EPS Y/Y TTM-1959.74% Oper. Margin-479.76% RSI (14)71.73 Volatility5.81% 5.69%
Employees339 Debt/Eq0.59 Sales Y/Y TTM-73.10% Profit Margin-332.47% Recom2.18 Target Price7.71
Option/ShortYes / Yes LT Debt/Eq0.51 EPS Q/Q-196.24% Payout- Rel Volume1.04 Prev Close3.74
Sales Surprise-48.43% EPS Surprise-34.66% Sales Q/Q-17.81% EarningsAug 06 AMC Avg Volume826.10K Price4.14
SMA2021.36% SMA5019.99% SMA200-55.17% Trades Volume860,315 Change10.70%
Date Action Analyst Rating Change Price Target Change
Aug-01-24Downgrade BTIG Research Buy → Neutral
Jul-31-24Downgrade Guggenheim Buy → Neutral
Jul-31-24Downgrade B. Riley Securities Buy → Neutral $18 → $5
May-10-24Downgrade TD Cowen Buy → Hold
May-10-24Downgrade Stifel Buy → Hold $29 → $7
May-10-24Downgrade BMO Capital Markets Outperform → Market Perform $24 → $8
Apr-26-24Initiated B. Riley Securities Buy $25
Apr-09-24Upgrade TD Cowen Hold → Buy
Mar-04-24Reiterated BTIG Research Buy $12 → $24
Feb-14-24Downgrade H.C. Wainwright Buy → Neutral $12 → $14
Sep-24-24 05:45AM
Sep-23-24 11:05AM
Sep-20-24 05:06AM
Sep-19-24 01:29PM
Sep-17-24 08:30AM
05:45AM Loading…
05:45AM
Sep-15-24 03:00AM
Sep-13-24 08:34AM
Sep-11-24 08:30AM
Sep-08-24 07:10PM
Sep-04-24 03:29PM
Sep-03-24 05:45AM
Sep-02-24 02:05PM
Aug-30-24 09:43AM
Aug-29-24 01:09PM
10:48AM Loading…
Aug-27-24 10:48AM
Aug-26-24 03:40PM
Aug-22-24 03:16PM
01:17PM
Aug-21-24 07:05AM
Aug-19-24 04:37PM
Aug-17-24 03:29PM
Aug-16-24 05:45AM
04:26AM
Aug-15-24 02:19PM
Aug-14-24 12:19PM
Aug-13-24 02:31PM
12:45AM
Aug-12-24 10:20AM
Aug-08-24 11:31AM
08:53AM Loading…
Aug-07-24 08:53AM
Aug-06-24 09:30PM
05:30PM
04:33PM
04:01PM
Jul-30-24 04:10PM
04:01PM
Jul-24-24 01:29PM
Jul-16-24 03:57PM
Jul-10-24 05:19PM
Jul-03-24 05:34PM
Jun-20-24 01:28PM
Jun-13-24 12:29PM
Jun-11-24 07:45AM
May-29-24 12:44PM
May-25-24 12:00PM
May-17-24 12:50PM
May-16-24 12:59PM
May-13-24 12:30PM
07:30AM
May-10-24 06:01PM
04:51PM
03:29PM
03:17PM
02:01PM
08:35AM
07:48AM
07:30AM
07:15AM
07:14AM
07:12AM
07:12AM
06:02AM
04:57AM
02:15AM
May-09-24 08:57PM
04:10PM
04:01PM
May-03-24 07:30AM
May-01-24 10:05AM
Apr-26-24 08:00AM
Apr-03-24 04:30PM
Mar-14-24 08:18AM
Mar-09-24 01:09PM
Mar-08-24 07:19AM
12:30AM
Mar-07-24 10:42PM
09:55PM
05:30PM
04:01PM
Mar-06-24 11:29PM
Mar-01-24 05:48PM
Feb-29-24 10:00AM
Feb-27-24 05:45PM
Feb-02-24 04:30PM
07:19AM
Jan-15-24 04:51PM
Jan-08-24 04:30PM
Dec-17-23 12:03PM
Nov-07-23 10:56AM
08:59AM
01:15AM
Nov-06-23 05:12PM
04:27PM
04:01PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Sep-05-23 07:00AM
Aug-31-23 04:30PM
Aug-19-23 07:40AM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGEL JAY PHILIPDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:34 PM
HEIDEN WILLIAM KDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:34 PM
Jackson Scott ThomasDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:34 PM
STUMP DAVID CDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
O'Brien Federica F.DirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
Liu MargaretDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
Chhabra MeenuDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
Ferrante Karen JeanDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:32 PM
HURWITZ EDWARDDirectorMay 20 '24Option Exercise0.004,500037,574May 22 04:32 PM
Peters Jeffrey StuartSenior VP and General CounselApr 04 '24Option Exercise4.8242,500204,85051,395Apr 08 06:07 PM
Peters Jeffrey StuartSenior VP and General CounselApr 04 '24Sale15.5551,395799,1480Apr 08 06:07 PM
Peters Jeffrey StuartSenior VP and General CounselMar 06 '24Option Exercise10.9019,625213,87528,520Mar 08 04:14 PM
Peters Jeffrey StuartSenior VP and General CounselMar 06 '24Sale21.5019,625421,9388,895Mar 08 04:14 PM
Risser Eric BlasiusChief Operating OfficerMar 04 '24Option Exercise10.1515,000152,25080,059Mar 06 04:20 PM
Risser Eric BlasiusChief Operating OfficerMar 04 '24Sale19.7641,159813,50138,900Mar 06 04:20 PM
Spitznagel ThomasSr VP, Technical OpsMar 04 '24Option Exercise11.5010,000115,00018,316Mar 06 04:19 PM
Spitznagel ThomasSr VP, Technical OpsMar 04 '24Sale20.0010,000200,0008,316Mar 06 04:19 PM
Karrels JamesSVP, CFO and SecretaryMar 04 '24Sale20.5030,000615,000171,452Mar 06 04:18 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 26 '24Sale17.2216,124277,6558,895Feb 28 04:20 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 22 '24Option Exercise0.0026,250035,145Feb 26 04:27 PM
Bonvini EzioSr VP, Research & CSOFeb 22 '24Option Exercise0.0028,1250110,258Feb 26 04:26 PM
Eck Stephen L.Chief Medical OfficerFeb 15 '24Option Exercise0.0016,670016,670Feb 20 06:41 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 15 '24Option Exercise0.0013,336013,336Feb 20 06:05 PM
Koenig ScottPresident and CEOFeb 15 '24Option Exercise0.0042,34101,091,977Feb 20 06:04 PM
Cilinski LynnVP, Controller and TreasurerFeb 15 '24Option Exercise0.006,66808,591Feb 20 06:04 PM
Risser Eric BlasiusChief Operating OfficerFeb 15 '24Option Exercise0.0016,670070,938Feb 20 06:04 PM
Karrels JamesSVP, CFO and SecretaryFeb 15 '24Option Exercise0.0015,0030206,779Feb 20 06:04 PM
Spitznagel ThomasSr VP, Technical OpsFeb 15 '24Option Exercise0.0013,336013,336Feb 20 06:03 PM
Bonvini EzioSr VP, Research & CSOFeb 15 '24Option Exercise0.0016,670088,004Feb 20 06:03 PM
Bonvini EzioSr VP, Research & CSOFeb 07 '24Sale18.003,33460,01271,334Feb 07 04:19 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 05 '24Option Exercise11.1176,251847,35576,251Feb 07 04:17 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 05 '24Sale16.5076,2511,258,1420Feb 07 04:17 PM
Bonvini EzioSr VP, Research & CSOFeb 01 '24Sale15.0013,316199,74074,668Feb 02 04:21 PM
Bonvini EzioSr VP, Research & CSOJan 19 '24Sale12.0013,316159,79287,984Jan 22 04:57 PM
Bonvini EzioSr VP, Research & CSODec 20 '23Sale10.0818,880190,310101,300Dec 21 04:12 PM